556 related articles for article (PubMed ID: 26467797)
21. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score.
Kim DW; Lee SS; Kim SO; Kim JH; Kim HJ; Byun JH; Yoo C; Kim KP; Song KB; Kim SC
Radiology; 2020 Sep; 296(3):541-551. PubMed ID: 32662759
[TBL] [Abstract][Full Text] [Related]
22. Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery.
Lee B; Yoon YS; Kang M; Park Y; Lee E; Jo Y; Lee JS; Lee HW; Cho JY; Han HS
Ann Surg Oncol; 2023 Jun; 30(6):3444-3454. PubMed ID: 36695994
[TBL] [Abstract][Full Text] [Related]
23. Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ductal adenocarcinoma.
Miyazawa M; Hirono S; Kawai M; Okada KI; Kitahata Y; Motobayashi H; Sato M; Yoshimura T; Ueno M; Hayami S; Miyamoto A; Shimizu A; Yamaue H
Eur J Surg Oncol; 2023 Oct; 49(10):106960. PubMed ID: 37353425
[TBL] [Abstract][Full Text] [Related]
24. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection.
Sugawara T; Ban D; Nishino J; Watanabe S; Maekawa A; Ishikawa Y; Akahoshi K; Ogawa K; Ono H; Kudo A; Tanaka S; Tanabe M
PLoS One; 2021; 16(4):e0249885. PubMed ID: 33844700
[TBL] [Abstract][Full Text] [Related]
25. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.
Aziz MH; Sideras K; Aziz NA; Mauff K; Haen R; Roos D; Saida L; Suker M; van der Harst E; Mieog JS; Bonsing BA; Klaver Y; Koerkamp BG; van Eijck CH
Ann Surg; 2019 Jul; 270(1):139-146. PubMed ID: 29334554
[TBL] [Abstract][Full Text] [Related]
26. Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer.
Imamura M; Nagayama M; Kyuno D; Ota S; Murakami T; Kimura A; Yamaguchi H; Kato T; Kimura Y; Takemasa I
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34064540
[TBL] [Abstract][Full Text] [Related]
27. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy.
Suto H; Okano K; Oshima M; Ando Y; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Suzuki Y
BMC Surg; 2019 Dec; 19(1):186. PubMed ID: 31796066
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
29. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
30. Predictive factors for early recurrence after pancreaticoduodenectomy in patients with resectable pancreatic head cancer: A multicenter retrospective study.
Ono S; Adachi T; Ohtsuka T; Kimura R; Nishihara K; Watanabe Y; Nagano H; Tokumitsu Y; Nanashima A; Imamura N; Baba H; Chikamoto A; Inomata M; Hirashita T; Furukawa M; Idichi T; Shinchi H; Maruyama Y; Nakamura M; Eguchi S
Surgery; 2022 Dec; 172(6):1782-1790. PubMed ID: 36123175
[TBL] [Abstract][Full Text] [Related]
31. Borderline resectable pancreatic cancer.
Hackert T; Ulrich A; Büchler MW
Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
[TBL] [Abstract][Full Text] [Related]
32. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
33. Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery.
Kondo N; Uemura K; Sumiyoshi T; Okada K; Seo S; Otsuka H; Kawano R; Murakami Y; Takahashi S
Dig Surg; 2021; 38(5-6):352-360. PubMed ID: 34689146
[TBL] [Abstract][Full Text] [Related]
34. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
35. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
36. A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: A multicenter study.
Zhang XP; Gao YX; Xu S; Zhao GD; Hu MG; Tan XL; Zhao ZM; Liu R
Int J Surg; 2022 Oct; 106():106891. PubMed ID: 36165934
[TBL] [Abstract][Full Text] [Related]
37. Postoperative Carbohydrate Antigen 19-9 Level as a Good Indicator of Ineffective Response to the Currently Recommended S-1 Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma: A Single-Center, Retrospective Study.
Ariake K; Okada T; Tsuchiya H; Kuboki D; Maemura K; Okada Y; Ichikawa H; Tachibana T; Akazawa N; Abe T; Kakita T; Oikawa M; Tsuchiya T
Ann Surg Oncol; 2024 Jan; 31(1):525-534. PubMed ID: 37851194
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
39. Effect of Risk Factor Score on Early Recurrence After Pancreatectomy for Invasive Pancreatic Ductal Adenocarcinoma.
Matsumoto M; Shirai Y; Abe K; Futagawa Y; Haruki K; Furukawa K; Onda S; Hamura R; Tanji Y; Tsunematsu M; Shiozaki H; Okamoto T; Ikegami T
Anticancer Res; 2024 Apr; 44(4):1695-1702. PubMed ID: 38537987
[TBL] [Abstract][Full Text] [Related]
40. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preoperative chemoradiotherapy.
Murata Y; Ogura T; Hayasaki A; Gyoten K; Ito T; Iizawa Y; Fujii T; Tanemura A; Kuriyama N; Kishiwada M; Sakurai H; Mizuno S
PLoS One; 2022; 17(4):e0264573. PubMed ID: 35377885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
